Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aussie Biotech Says Millions In Royalties Lost To Medical Institutions

This article was originally published in PharmAsia News

Executive Summary

The Australian biotech Genetic Technologies says publicly funded institutions are violating its patents to the tune of about $12.6 million a year. The company objected to the alleged violations as a Senate panel considered barring patents on genetic intellectual property. Paul MacLeman, CEO of Genetic, which specializes in testing DNA, said the medical institutions screen for breast cancer at commercial rates, but pay no royalties to the owner of the patents for those tests. When Genetic sought to enforce its patents last year, it had to back off after a public outcry. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts